Welcome to our dedicated page for Lifestance Health Group news (Ticker: LFST), a resource for investors and traders seeking the latest updates and insights on Lifestance Health Group stock.
LifeStance Health Group reports developments as a Nasdaq-listed provider of virtual and in-person outpatient mental healthcare. The company serves children, adolescents and adults through psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy.
Recurring news themes include quarterly operating results, visit volumes, clinician productivity, center-level margin trends, cash flow, debt and capital allocation. Company updates also cover secondary common stock offerings by selling stockholders, share repurchase activity, investor conference presentations, executive and board changes, and corporate-status announcements tied to its outpatient mental health services business.
LifeStance Health Group (Nasdaq: LFST) priced a secondary offering of 35,000,000 common shares at $8.15 per share on May 7, 2026. The Selling Stockholders will receive all proceeds; LifeStance is not selling shares and will not receive offering proceeds.
The company agreed to a conditional Repurchase of 6,000,000 shares from the selling holders at the same price; the Repurchase is conditioned on closing and customary conditions. Settlement is expected on or about May 12, 2026, with J.P. Morgan as underwriter.
LifeStance Health Group (Nasdaq: LFST) announced that certain selling stockholders intend to offer 35,000,000 shares of common stock in a secondary offering on May 7, 2026. The Company will not sell shares or receive proceeds from that offering.
LifeStance authorized a concurrent repurchase of 6,000,000 shares from the underwriter, at the same per-share price paid by the underwriter to the selling stockholders; the underwriter will not receive underwriting fees on repurchased shares. J.P. Morgan is the underwriter. The offering relies on a shelf registration that became effective May 21, 2024.
LifeStance Health (Nasdaq: LFST) reported Q1 2026 results: revenue $403.5M (+21% YoY), clinicians 8,349 (+11%), visits 2.5M (+18%), net income $14.2M, and Adjusted EBITDA $51.1M (+48%).
Cash from operations was $33.1M, free cash flow $22.3M, ending cash $194.8M and net long-term debt $262.5M. Full-year 2026 guidance raised to $1.64B–$1.68B revenue and $200M–$220M Adjusted EBITDA.
LifeStance Health (NASDAQ: LFST) said management will present at two investor conferences in May and June 2026.
Details: Dave Bourdon, CEO, will present at the Bank of America 2026 Healthcare Conference on May 13, 2026 (5:00 p.m. PT, Encore at the Wynn, Las Vegas) and at the William Blair 46th Annual Growth Stock Conference on June 4, 2026 (11:20 a.m. CT, Loews Chicago Hotel, Chicago).
Both presentations will be webcast live and a replay will be available on the LifeStance investor website.
LifeStance Health Group (NASDAQ: LFST) will be added to the S&P SmallCap 600 prior to trading on May 1, 2026. Golden Entertainment (NASDAQ: GDEN) will be deleted from the index on the same date, following a pending acquisition by VICI Properties and Blake Sartini.
The table of changes lists LFST as an addition to the Health Care sector and GDEN as a deletion from Consumer Discretionary.
LifeStance Health Group (NASDAQ: LFST) will release its first quarter 2026 earnings before the market opens on Thursday, May 7, 2026, and host a live conference call at 8:30 a.m. ET.
Investors can join by dialing 1-800-715-9871 (U.S.) or 1-646-307-1963 (international) with conference ID 8795477, or listen via the company's Investor Relations Events and Presentations webcast. Related materials and a replay will be posted on the Investor Relations website.
LifeStance (NASDAQ:LFST) published clinical outcomes from an analysis of nearly 180,000 patients who began care between Sept 2024 and Dec 2025. The results show 79% of patients had clinically significant anxiety improvement and 73% had clinically significant depression improvement.
Assessments used the GAD-7 and PHQ-9, findings were consistent across all 33 states served, and LifeStance attributes results to its measurement-informed care model combining therapy, medication management, in-person and telehealth options.
LifeStance Health Group (Nasdaq: LFST) announced on February 25, 2026 that certain selling stockholders intend to offer 25,000,000 shares of common stock under an existing shelf registration. The company will not sell shares and will not receive proceeds.
LifeStance authorized a concurrent repurchase of 7,000,000 shares from the underwriter, subject to the offering’s completion and customary conditions; J.P. Morgan is the underwriter. The shelf registration became effective on May 21, 2024. The repurchase price will match the offering price and the underwriter will not receive fees on repurchased shares.
LifeStance (Nasdaq: LFST) reported Q4 2025 revenue of $382.2M (up 17%) and full-year revenue of $1,424.3M (up 14%). FY Adjusted EBITDA was $157.7M and net income was $9.7M. The company generated $146.2M cash from operations and ended Q4 with $248.6M cash and $265.9M net long-term debt. The Board approved a $100M share repurchase program and provided 2026 guidance calling for $1.615B–$1.655B revenue and $185M–$205M Adjusted EBITDA.
LifeStance Health (NASDAQ: LFST) will release fourth quarter and full year 2025 results before the market opens on Wednesday, February 25, 2026, and will host a live earnings conference call the same day at 8:30 a.m. ET.
Investors may join by phone using conference ID 3993891 or listen via the LifeStance Investor Relations webcast; replay and related materials will be posted on the IR website.